Advertisement
Singapore markets close in 1 hour 11 minutes
  • Straits Times Index

    3,300.17
    -13.88 (-0.42%)
     
  • Nikkei

    38,946.93
    -122.75 (-0.31%)
     
  • Hang Seng

    19,265.17
    -371.05 (-1.89%)
     
  • FTSE 100

    8,398.87
    -25.33 (-0.30%)
     
  • Bitcoin USD

    70,902.42
    +4,046.36 (+6.05%)
     
  • CMC Crypto 200

    1,527.84
    +39.30 (+2.64%)
     
  • S&P 500

    5,308.13
    +4.86 (+0.09%)
     
  • Dow

    39,806.77
    -196.82 (-0.49%)
     
  • Nasdaq

    16,794.88
    +108.91 (+0.65%)
     
  • Gold

    2,422.40
    -16.10 (-0.66%)
     
  • Crude Oil

    79.25
    -0.55 (-0.69%)
     
  • 10-Yr Bond

    4.4370
    +0.0170 (+0.38%)
     
  • FTSE Bursa Malaysia

    1,622.87
    -4.63 (-0.28%)
     
  • Jakarta Composite Index

    7,214.74
    -51.96 (-0.72%)
     
  • PSE Index

    6,633.66
    -49.12 (-0.74%)
     

Insights Into Astrazeneca (AZN) Q1: Wall Street Projections for Key Metrics

In its upcoming report, Astrazeneca (AZN) is predicted by Wall Street analysts to post quarterly earnings of $0.95 per share, reflecting a decline of 1% compared to the same period last year. Revenues are forecasted to be $11.94 billion, representing a year-over-year increase of 9.7%.

Over the last 30 days, there has been a downward revision of 1.7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.

Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.

While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.

ADVERTISEMENT

That said, let's delve into the average estimates of some Astrazeneca metrics that Wall Street analysts commonly model and monitor.

The collective assessment of analysts points to an estimated 'Product Sales- CVRM- Brilinta' of $310.25 million. The estimate indicates a year-over-year change of -7.1%.

The consensus among analysts is that 'Product Sales- CVRM- Onglyza' will reach $49.01 million. The estimate indicates a change of -22.2% from the prior-year quarter.

Analysts predict that the 'Product Sales- CVRM- Farxiga' will reach $1.62 billion. The estimate points to a change of +24.9% from the year-ago quarter.

The average prediction of analysts places 'Product Sales- Oncology- Lynparza' at $724.52 million. The estimate indicates a change of +11.3% from the prior-year quarter.

According to the collective judgment of analysts, 'Fasenra- U.S. Sales' should come in at $227.69 million. The estimate indicates a year-over-year change of +13.3%.

The combined assessment of analysts suggests that 'Brilinta- U.S. Sales' will likely reach $167.43 million. The estimate points to a change of -6.5% from the year-ago quarter.

It is projected by analysts that the 'Onglyza- U.S. Sales' will reach $6.32 million. The estimate indicates a change of -54.8% from the prior-year quarter.

Analysts expect 'Lynparza- U.S. Sales' to come in at $302.51 million. The estimate indicates a change of +12.9% from the prior-year quarter.

The consensus estimate for 'Imfinzi- U.S. Sales' stands at $635.60 million. The estimate suggests a change of +21.8% year over year.

Analysts' assessment points toward 'Calquence- U.S. Sales' reaching $442.60 million. The estimate indicates a change of +15.3% from the prior-year quarter.

Analysts forecast 'Farxiga- U.S. Sales' to reach $400.36 million. The estimate indicates a change of +35.3% from the prior-year quarter.

Based on the collective assessment of analysts, 'Lokelma- U.S. Sales' should arrive at $64.23 million. The estimate indicates a change of +14.7% from the prior-year quarter.

View all Key Company Metrics for Astrazeneca here>>>

Over the past month, Astrazeneca shares have recorded returns of +3.5% versus the Zacks S&P 500 composite's -4% change. Based on its Zacks Rank #3 (Hold), AZN will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AstraZeneca PLC (AZN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research